New industrial orders in Germany increased month on month in December 2021

Big Pharma CCHT’s Domination Unlikely to Fade Soon Despite Official Bulk Buying

The producer of long-acting growth hormone acupunctures, vaccines and other drugs, looks set to offset the effects of so-called “centralized procurement” on its product prices with more aggressive expansion into private hospitals. So far, its monopoly appears unshakable, but with more competitors upping the stakes, how long will it last?

Alphamab Licenses Cancer Drug to Pathos AI in Deal Worth More Than US$2.2 Billion

Alphamab Oncology (康宁杰瑞生物制药) has licensed the overseas rights to its experimental cancer drug JSKN016 to US-based Pathos AI in a deal potentially worth more than US$2.2 billion, marking another major overseas licensing agreement for China’s rapidly expanding innovative-drug sector.

Beyond Capital: Why Europe Needs Industrial Partners, Not Just Investors

Europe’s reindustrialization is creating new opportunities for Chinese companies. However, the winners will not necessarily be those seeking quick acquisitions or rapid market access. The real opportunities belong to companies capable of embedding themselves into Europe’s industrial ecosystem and supporting the long-term transformation of local industries.

Mabwell Signs GCC Licensing Deal with Saudi Arabia’s SVAX for Aflibercept Biosimilar

Mabwell (Shanghai) Bioscience Co., Ltd.（迈威（上海）生物科技股份有限公司）has entered into a licensing agreement with Saudi Arabian biopharmaceutical company SVAX Inc. covering its aflibercept biosimilar, 9MW0813, in the Gulf Cooperation Council market.

Insilico Medicine (英矽智能) Signs Strategic Drug Discovery Partnership with Takeda (武田制药), Deal Worth Up to US$600 Million

Chinese AI drug discovery company Insilico Medicine (英矽智能) has signed a global strategic collaboration with Japanese pharmaceutical company Takeda (武田制药), with the total potential deal value reaching up to US$600 million. Announced in early July, the agreement marks another milestone in the international commercialization of China's AI-powered drug discovery technologies through collaboration with a leading multinational pharmaceutical company.